Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Editor's Note
There are a lot of prescribers who are mixing DPP-4 inhibitors and SGLT-2 inhibitors to manage glucose levels.The recent research showing the value of SGLT-2 inhibitors on cardiovascular outcomes has led this addition to the diabetes mix, especially since cardiovascular disease is greatly increased in diabetes patients. This week, we have a special feature on another reason to use these two classes together. Plus, we have another feature showing that using a DPP-4 inhibitor can provide vascular protection, thereby further helping our diabetes patients.
Dave Joffe
Editor-in-chief
The DPP-IV inhibitor sitagliptin was safe and effective over 3 years for adults aged at least 75 years who had well-controlled type 2 diabetes and cardiovascular disease, findings from an analysis of TECOS study data show.
We know from previous studies that obesity and type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease.
A DPP-4 inhibitor can help to prevent kidney function and did not have any negative cardiovascular effects.